MX2009011783A - Inhibidores de iap. - Google Patents
Inhibidores de iap.Info
- Publication number
- MX2009011783A MX2009011783A MX2009011783A MX2009011783A MX2009011783A MX 2009011783 A MX2009011783 A MX 2009011783A MX 2009011783 A MX2009011783 A MX 2009011783A MX 2009011783 A MX2009011783 A MX 2009011783A MX 2009011783 A MX2009011783 A MX 2009011783A
- Authority
- MX
- Mexico
- Prior art keywords
- iap
- inhibitors
- general formula
- compounds
- useful
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91501007P | 2007-04-30 | 2007-04-30 | |
| PCT/US2008/061891 WO2008134679A1 (en) | 2007-04-30 | 2008-04-29 | Inhibitors of iap |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011783A true MX2009011783A (es) | 2009-12-04 |
Family
ID=39926122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011783A MX2009011783A (es) | 2007-04-30 | 2008-04-29 | Inhibidores de iap. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8907092B2 (OSRAM) |
| EP (1) | EP2148858A4 (OSRAM) |
| JP (1) | JP5368428B2 (OSRAM) |
| KR (1) | KR20100024923A (OSRAM) |
| CN (1) | CN101687787A (OSRAM) |
| AR (1) | AR066348A1 (OSRAM) |
| AU (1) | AU2008245447C1 (OSRAM) |
| BR (1) | BRPI0809867A2 (OSRAM) |
| CA (1) | CA2683392A1 (OSRAM) |
| CL (1) | CL2008001234A1 (OSRAM) |
| IL (1) | IL201379A0 (OSRAM) |
| MX (1) | MX2009011783A (OSRAM) |
| NZ (2) | NZ598890A (OSRAM) |
| PE (2) | PE20090211A1 (OSRAM) |
| RU (1) | RU2491276C2 (OSRAM) |
| TW (1) | TWI432212B (OSRAM) |
| WO (1) | WO2008134679A1 (OSRAM) |
| ZA (1) | ZA200906946B (OSRAM) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
| KR20120127754A (ko) * | 2004-12-20 | 2012-11-23 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| PL1851200T3 (pl) | 2005-02-25 | 2014-06-30 | Tetralogic Pharm Corp | Dimeryczne inhibitory IAP |
| US7772177B2 (en) | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| WO2008014263A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| EP2049524A2 (en) | 2006-07-24 | 2009-04-22 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
| KR20100110870A (ko) * | 2008-01-11 | 2010-10-13 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| WO2009094224A1 (en) | 2008-01-25 | 2009-07-30 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| AU2009279924B2 (en) | 2008-08-02 | 2014-10-02 | Genentech, Inc. | Inhibitors of IAP |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9139589B2 (en) | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CA2763638A1 (en) * | 2009-05-28 | 2010-12-02 | Tetralogic Pharmaceuticals Corp. | Iap inhibitors |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US8362068B2 (en) | 2009-12-18 | 2013-01-29 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| EP2603216A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| TW201217365A (en) | 2010-08-11 | 2012-05-01 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| UY33671A (es) | 2010-10-13 | 2012-04-30 | Millenium Pharmaceuticals Inc | Heteroarilos y sus usos |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| NO2755614T3 (OSRAM) | 2012-01-03 | 2018-03-31 | ||
| HK1208875A1 (en) | 2012-01-12 | 2016-03-18 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| WO2013166344A1 (en) | 2012-05-04 | 2013-11-07 | Novartis Ag | Biomarkers for iap inhibitor therapy |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| EA035253B1 (ru) | 2013-03-15 | 2020-05-21 | Новартис Аг | Лекарственные конъюгаты антител |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10300074B2 (en) | 2014-06-04 | 2019-05-28 | Sanford Burnham Prebys Medical Discovery Institute | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| MA40513A (fr) | 2014-08-12 | 2017-06-21 | Novartis Ag | Conjugués médicament-anticorps anti-cdh6 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CA2974367A1 (en) | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
| US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| RS64976B1 (sr) | 2016-12-01 | 2024-01-31 | Arvinas Operations Inc | Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| JP7679173B2 (ja) | 2016-12-23 | 2025-05-19 | アルビナス・オペレーションズ・インコーポレイテッド | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| CN117551089A (zh) | 2017-01-26 | 2024-02-13 | 阿尔维纳斯运营股份有限公司 | 雌激素受体蛋白水解调节剂及相关使用方法 |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| EP3592868B1 (en) | 2017-03-06 | 2022-11-23 | Novartis AG | Methods of treatment of cancer with reduced ubb expression |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| CN111107868A (zh) | 2017-05-24 | 2020-05-05 | 诺华股份有限公司 | 抗体细胞因子移植蛋白及使用方法 |
| MX2019014023A (es) | 2017-05-24 | 2020-02-17 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer. |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| CA3068350A1 (en) | 2017-06-30 | 2019-01-03 | Bayer Animal Health Gmbh | New azaquinoline derivatives |
| WO2019090269A1 (en) * | 2017-11-06 | 2019-05-09 | Peng Wang | Processes to produce acalabrutinib |
| CN109836416B (zh) * | 2017-11-27 | 2023-02-03 | 苏州鹏旭医药科技有限公司 | 一种化合物的制备方法 |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| JP7720698B2 (ja) | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| PL3820573T3 (pl) | 2018-07-10 | 2024-02-19 | Novartis Ag | Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2) |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| US20230053449A1 (en) | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
| CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
| JP7607564B2 (ja) | 2018-12-21 | 2024-12-27 | ノバルティス アーゲー | Ｐｍｅｌ１７に対する抗体及びその結合体 |
| JP7483732B2 (ja) | 2019-02-15 | 2024-05-15 | ノバルティス アーゲー | ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN114867727B (zh) | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| EP4004221A4 (en) * | 2019-07-25 | 2023-10-25 | Lanzatech, Inc. | SECONDARY ACETATE FERMENTATION |
| JP2022542437A (ja) | 2019-08-02 | 2022-10-03 | ランティオペプ ベスローテン ヴェンノーツハップ | 癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| TW202135859A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 組合療法 |
| AU2021211871A1 (en) | 2020-01-20 | 2022-09-08 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| KR20230024967A (ko) | 2020-06-11 | 2023-02-21 | 노파르티스 아게 | Zbtb32 억제제 및 이의 용도 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| JP2023541434A (ja) | 2020-09-14 | 2023-10-02 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体の標的化分解のための化合物の結晶性形態 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| KR20230170738A (ko) | 2021-04-16 | 2023-12-19 | 노파르티스 아게 | 항체 약물 접합체 및 이의 제조 방법 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| CN119301125A (zh) | 2022-07-26 | 2025-01-10 | 诺华股份有限公司 | Akr1c3依赖性kars抑制剂的晶型 |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| JP2025535017A (ja) * | 2022-09-29 | 2025-10-22 | トラクト ファーマシューティカルズ インコーポレイテッド | Ｉａｐの阻害剤として有用な化合物及び組成物 |
| KR20250151412A (ko) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론계 kras 분해 단백질 및 이와 관련된 용도 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE430062B (sv) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
| DE2714880A1 (de) | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE3685626T2 (de) | 1985-09-26 | 1993-01-28 | Beckmann Research Inst Of The | Sequenzierung von peptiden. |
| US4935494A (en) | 1988-11-15 | 1990-06-19 | City Of Hope | C-terminal peptide and protein sequencing |
| CA2012306A1 (en) | 1989-03-28 | 1990-09-28 | Werner Neidhart | Amino acid derivatives |
| DK167813B1 (da) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| WO1992001938A1 (en) | 1990-07-20 | 1992-02-06 | City Of Hope | Derivatization of c-terminal proline |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5559209A (en) | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| SK56798A3 (en) | 1995-10-30 | 1998-12-02 | Smithkline Beecham Corp | Protease inhibitors, pharmaceutical composition containing them and their use |
| WO1998046597A1 (en) | 1997-04-14 | 1998-10-22 | Emory University | Serine protease inhibitors |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6472172B1 (en) | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
| EP1141708A1 (en) | 1998-12-28 | 2001-10-10 | Sunesis Pharmaceuticals Inc. | Identifying small organic molecule ligands for binding |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| CA2420534A1 (en) | 2000-08-24 | 2002-02-28 | Thomas Jefferson University | An iap binding peptide or polypeptide and methods of using the same |
| WO2002026775A2 (en) | 2000-09-29 | 2002-04-04 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
| US7718600B2 (en) | 2000-09-29 | 2010-05-18 | The Trustees Of Princeton University | IAP binding compounds |
| WO2002096930A2 (en) | 2001-05-31 | 2002-12-05 | The Trustees Of Princeton University | Iap binding peptides and assays for identifying compounds that bind iap |
| US6992063B2 (en) | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
| WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
| AU2002253908A1 (en) | 2001-02-08 | 2003-02-17 | Thomas Jefferson University | A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis |
| EP1373263B1 (en) | 2001-04-05 | 2004-10-27 | Torrent Pharmaceuticals Ltd | Heterocyclic compounds for aging-related and diabetic vascular complications |
| US20030157522A1 (en) | 2001-11-09 | 2003-08-21 | Alain Boudreault | Methods and reagents for peptide-BIR interaction screens |
| WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| WO2004005248A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| WO2004017991A1 (en) | 2002-08-13 | 2004-03-04 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas |
| JP4315249B2 (ja) | 2003-02-07 | 2009-08-19 | ジェネンテック・インコーポレーテッド | アポトーシス亢進のための組成物と方法 |
| US20040171554A1 (en) | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
| IL156263A0 (en) | 2003-06-02 | 2004-01-04 | Hadasit Med Res Service | Livin-derived peptides, compositions and uses thereof |
| AU2004291936A1 (en) | 2003-11-13 | 2005-06-02 | Burnham Institute | Compositions and methods for screening pro-apoptotic compounds |
| CA2553874A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| US20100093645A1 (en) | 2004-01-16 | 2010-04-15 | Shaomeng Wang | SMAC Peptidomimetics and the Uses Thereof |
| EP1723122B1 (en) * | 2004-03-01 | 2014-11-19 | Board of Regents, The University of Texas System | Dimeric small molecule potentiators of apoptosis |
| EP1740173A4 (en) * | 2004-03-23 | 2009-05-27 | Genentech Inc | AZABICYCLOOCTAN IAP INHIBITORS |
| RS52545B (sr) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| PT1778718E (pt) | 2004-07-02 | 2014-12-03 | Genentech Inc | Inibidores de iap |
| EA200700225A1 (ru) | 2004-07-12 | 2008-02-28 | Айдан Фармасьютикалз, Инк. | Аналоги тетрапептида |
| AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
| KR20120127754A (ko) | 2004-12-20 | 2012-11-23 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| PL1851200T3 (pl) | 2005-02-25 | 2014-06-30 | Tetralogic Pharm Corp | Dimeryczne inhibitory IAP |
| US7772177B2 (en) | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
| WO2007048224A1 (en) * | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| AU2006340014B2 (en) | 2005-12-19 | 2012-12-20 | Genentech, Inc. | Inhibitors of IAP |
| TWI543988B (zh) * | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| CA2646186A1 (en) | 2006-03-21 | 2007-11-29 | Joyant Pharmaceuticals, Inc. | Small molecule apoptosis promoters |
| US20100143499A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110217A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2666112A1 (en) | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as iap inhibitors |
| EP2125809A1 (en) | 2006-12-19 | 2009-12-02 | Genentech, Inc. | Imidazopyridine inhibitors of iap |
| KR20100110870A (ko) | 2008-01-11 | 2010-10-13 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| AU2009279924B2 (en) | 2008-08-02 | 2014-10-02 | Genentech, Inc. | Inhibitors of IAP |
| NZ590500A (en) | 2008-08-16 | 2012-06-29 | Genentech Inc | Azaindole inhibitors of iap |
-
2008
- 2008-04-29 CL CL200801234A patent/CL2008001234A1/es unknown
- 2008-04-29 KR KR1020097024828A patent/KR20100024923A/ko not_active Abandoned
- 2008-04-29 NZ NZ598890A patent/NZ598890A/xx not_active IP Right Cessation
- 2008-04-29 PE PE2008000757A patent/PE20090211A1/es not_active Application Discontinuation
- 2008-04-29 US US12/598,027 patent/US8907092B2/en not_active Expired - Fee Related
- 2008-04-29 JP JP2010506573A patent/JP5368428B2/ja not_active Expired - Fee Related
- 2008-04-29 BR BRPI0809867-0A patent/BRPI0809867A2/pt not_active IP Right Cessation
- 2008-04-29 TW TW097115740A patent/TWI432212B/zh not_active IP Right Cessation
- 2008-04-29 WO PCT/US2008/061891 patent/WO2008134679A1/en not_active Ceased
- 2008-04-29 MX MX2009011783A patent/MX2009011783A/es not_active Application Discontinuation
- 2008-04-29 NZ NZ580226A patent/NZ580226A/xx not_active IP Right Cessation
- 2008-04-29 RU RU2009144094/04A patent/RU2491276C2/ru not_active IP Right Cessation
- 2008-04-29 EP EP08747109A patent/EP2148858A4/en not_active Withdrawn
- 2008-04-29 CN CN200880022901A patent/CN101687787A/zh active Pending
- 2008-04-29 CA CA002683392A patent/CA2683392A1/en not_active Abandoned
- 2008-04-29 AR ARP080101812A patent/AR066348A1/es not_active Application Discontinuation
- 2008-04-29 PE PE2012001805A patent/PE20130150A1/es not_active Application Discontinuation
- 2008-04-29 AU AU2008245447A patent/AU2008245447C1/en not_active Ceased
-
2009
- 2009-10-06 ZA ZA2009/06946A patent/ZA200906946B/en unknown
- 2009-10-11 IL IL201379A patent/IL201379A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200906946B (en) | 2011-05-25 |
| EP2148858A1 (en) | 2010-02-03 |
| JP2010526079A (ja) | 2010-07-29 |
| NZ598890A (en) | 2013-10-25 |
| PE20130150A1 (es) | 2013-02-27 |
| AU2008245447B2 (en) | 2014-01-23 |
| TWI432212B (zh) | 2014-04-01 |
| CA2683392A1 (en) | 2008-11-06 |
| WO2008134679A1 (en) | 2008-11-06 |
| IL201379A0 (en) | 2010-05-31 |
| AU2008245447C1 (en) | 2014-11-20 |
| NZ580226A (en) | 2012-11-30 |
| RU2491276C2 (ru) | 2013-08-27 |
| PE20090211A1 (es) | 2009-04-02 |
| JP5368428B2 (ja) | 2013-12-18 |
| US8907092B2 (en) | 2014-12-09 |
| EP2148858A4 (en) | 2011-01-26 |
| CL2008001234A1 (es) | 2008-09-22 |
| AU2008245447A1 (en) | 2008-11-06 |
| RU2009144094A (ru) | 2011-06-10 |
| US20110077265A1 (en) | 2011-03-31 |
| BRPI0809867A2 (pt) | 2014-09-30 |
| AR066348A1 (es) | 2009-08-12 |
| CN101687787A (zh) | 2010-03-31 |
| KR20100024923A (ko) | 2010-03-08 |
| TW200902067A (en) | 2009-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011783A (es) | Inhibidores de iap. | |
| IL183514A0 (en) | Pyrrolidine inhibitors of iap | |
| TW200716606A (en) | Chemical compounds | |
| TW200800963A (en) | Chemical compounds | |
| SI1853602T1 (sl) | Kemične spojine | |
| PT1853588E (pt) | Compostos químicos | |
| WO2007106192A3 (en) | Inhibitors of iap | |
| PH12013501489A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| TW200942533A (en) | Pyridyl inhibitors of hedgehog signalling | |
| MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
| TN2009000049A1 (en) | A pyrrolopyrazin as syk-kinase inhibitor | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| UA94749C2 (en) | Benzimidazole modulators of vr1 | |
| ATE523487T1 (de) | 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung | |
| MY153763A (en) | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | |
| MX2010007543A (es) | Inhibidores de iap. | |
| TW200745028A (en) | Novel sulphonylpyrroles | |
| GB2466912A (en) | Compositions and methods for treating lysosomal disorders | |
| MX2009011753A (es) | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. | |
| WO2010021934A3 (en) | Azaindole inhibitors of iap | |
| TW200745027A (en) | Novel sulphonylpyrroles | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| TW200616977A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
| UA85701C2 (ru) | Способ получения ингибиторов триптазы | |
| TW200719889A (en) | Amino acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |